1. Home
  2. AKTX

as 05-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Founded: N/A Country:
United Kingdom
United Kingdom
Employees: N/A City: BOSTON
Market Cap: 12.0M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 18.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.05 EPS Growth: N/A
52 Week Low/High: $1.08 - $5.50 Next Earning Date: 05-16-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: